scholarly journals Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients

2020 ◽  
Vol 23 (3) ◽  
pp. 259
Author(s):  
Jean Schneider ◽  
Hyouk Jin Lee ◽  
Seok Jin Nam ◽  
Soo Jung Lee ◽  
Jin Hyang Jung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Survival Benefit ◽  
Relative Survival ◽  
Breast Cancer Patients ◽  
Receptor Status ◽  
Hormonal Receptor ◽  
Hormonal Receptor Status

Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

2017 ◽  
Vol 24 (12) ◽  
pp. 3510-3517 ◽  
Author(s):  
John R. Bergquist ◽  
Brittany L. Murphy ◽  
Curtis B. Storlie ◽  
Elizabeth B. Habermann ◽  
Judy C. Boughey
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Treatment Response ◽  
Cancer Patients ◽  
Tumor Grade ◽  
Breast Cancer Patients ◽  
Receptor Status

scholarly journals A Call to Re-evaluate Receptor Status for Breast Cancer Patients after Neoadjuvant Chemotherapy

2021 ◽  
Vol 233 (5) ◽  
pp. S31
Author(s):  
Jin Huang ◽  
Victoria Huynh ◽  
Gretchen M. Ahrendt ◽  
Anosheh Afghahi ◽  
Sharon Sams ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Receptor Status

Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

2007 ◽  
Vol 12 (6) ◽  
pp. 636-643 ◽  
Author(s):  
Olivier Tacca ◽  
Frédérique Penault‐Llorca ◽  
Catherine Abrial ◽  
Marie‐Ange Mouret‐Reynier ◽  
Inès Raoelfils ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Prognostic Value ◽  
Hormone Receptor Status ◽  
Operable Breast Cancer ◽  
Breast Cancer Patients ◽  
Receptor Status

The Hormonal Receptor Status in Breast Cancer can be Altered by Neoadjuvant Chemotherapy: A Meta-Analysis

2011 ◽  
Vol 29 (9) ◽  
pp. 594-598 ◽  
Author(s):  
Ning Zhang ◽  
Meena S. Moran ◽  
Qiang Huo ◽  
Bruce G. Haffty ◽  
Qifeng Yang
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Meta Analysis ◽  
Receptor Status ◽  
Hormonal Receptor ◽  
Hormonal Receptor Status

scholarly journals Association of Oral Contraceptives use with Breast Cancer and Hormone Receptor Status in Iraqi Women

2020 ◽  
Vol 8 (B) ◽  
pp. 1244-1250
Author(s):  
Ahmed Z. Alsammarraie ◽  
Ahmed A. Mubarak ◽  
Ahmed S. Alnuaimi ◽  
Areege M. Kamal
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Oral Contraceptives ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Breast Cancer Patients ◽  
Receptor Status ◽  
History Of ◽  
Iraqi Women ◽  
Hormonal Receptor Status

BACKGROUND: Worldwide, there is a significant concern regarding the association of breast cancer risk and oral contraceptives use. Differences in demographical and pathological breast cancer characteristics in Iraqi patients have been reported compared to other western countries; however, studies addressing the risk of breast cancer among oral contraceptive users in Iraq and subsequent correlation with hormonal receptor status are lacking. AIM: The aim of the study was to evaluate association of breast cancer risk and oral contraceptives use in patients visiting tertiary oncology center and to correlate hormone receptor status with history of oral contraception use in breast cancer patients. PATIENTS AND METHODS: Two hundred women with breast cancer were compared regarding patterns of oral contraceptives use with 300 age-matched healthy female controls by personal interview and questionnaire. Patient’s records were reviewed for hormone receptor status. RESULTS: A significantly higher proportion (49%) of women with breast cancer reported a positive history of combined oral contraceptives use as compared with (35.7%) healthy controls. Ever oral contraceptives users had a significantly increased risk of breast cancer (odds ratio [OR] = 1.73; 95%, confidence interval = 1.2–2.5, p = 0.003), with the highest risk was seen in early use before the age of 20 (OR = 6.62, p = 0.02); whereas increased duration of use did not significantly increase the risk of breast cancer. There was no significant association between estrogen and progesterone receptors expression profile in breast cancer patients and combined oral contraceptive use. CONCLUSION: In Iraqi women, the risk of breast cancer increases with oral contraceptives intake particularly when starts early before the age of 20 years. The hormonal receptor status of breast cancer patients is not significantly affected by combined oral contraceptives use.

Sign in / Sign up

Export Citation Format

Share Document